Skip to main content

Table 1 Patient characteristics

From: 5-year outcomes of salvage endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma

Patient # Age at surgery / Gender Ethnicity cTNM cStage WHO classd Time of diagnosisa Initial treatment Open procedure / Timeb Follow-upc (months)
P1 61.9 / M Caucasian T2N2M0 Stage 3 III 24.4 60 Gy to nasopharynx No 56.4
P2 50.3 / M Taiwanese T1N2M0 Stage 3 III 48.5 70 Gy to nasopharynx, 50 Gy to neck + chemo (5-FU, cisplatin) No 57.2
P3 45.8 / M Chinese T1N0M0 Stage 1 II 36.2 IMRT (70 Gy to nasopharynx, 54 Gy to neck) No 70.7
P4 60.4 / F Japanese T2N1M0 Stage 2 II 54.2 IMRT (70 Gy) + Chemo (cisplatin, 5-FU) Yes / 36.7 70.5
P5 60.4 / M African American T1N0M0 Stage 1 III 5.2 IMRT (70 Gy to nasopharynx, 54 Gy to neck) No 94.9
P6 80.8 / F Chinese T1N0M0 Stage 1 III 13.1 IMRT (70 Gy) No 93.6
P7 34.9 / F Taiwanese T3N1M0 Stage 3 II 24.8 IMRT (70 Gy) + Chemo (cisplatin, 5-FU, bevacizumab) No 89.1
P8 70.5 / M Taiwanese T3N0M0 Stage 3 III 168 External beam radiation Yes / 86.8 96
P9 63.8 / M Filipino T1N1M0 Stage 2 III 24.0 IMRT (66.6 Gy to nasopharynx, 59.4 Gy to neck) + Chemo (cisplatin) No 86
P10 69.9 / M Filipino T1N1M0 Stage 2 II 13.0 IMRT (70 Gy to nasopharynx, 56.4 Gy to neck) No 67.2
P11 42.5 / M Chinese T1N3M0 Stage 4a III 84.7 70 Gy to nasopharynx, 72 Gy to neck + Chemo (5-FU, cisplatin) Yes / 36.4 60.6
P12 45.5 / M Chinese T1N2M0 Stage 3 III 4.2 IMRT (70 Gy) + Chemo (5-FU, cisplatin) No 82.2
P13 44.6 / F Chinese T1N2M0 Stage 3 I 156 Radiation + Chemo Yes / 145 78.2
  1. a“Time of diagnosis” of the presenting nasopharyngeal carcinoma is denoted by the number of months the diagnosis was made prior to the first endoscopic nasopharyngectomy
  2. b“Time” of open nasopharyngectomy is denoted by the number of months the procedure was performed prior to the first endoscopic nasopharyngectomy
  3. c“Follow-up” is calculated as the number of months of patient follow-up after the first endoscopic nasopharyngectomy
  4. dTumor classifications: I = keratinizing, II = non-keratinizing, III = undifferentiated, non-keratinizing, associated with EBV